Table 5.
Multivariate analysis of prognostic factors (validation cohort)
| Overall survival |
p value (Cox regression) |
||
|---|---|---|---|
| HR | 95% CI | ||
| Child-Pugh score | |||
| A | 1 | ||
| B | 1.58 | 1.23-2.03 | <0.001 |
| C | 1.65 | 0.48-5.69 | 0.425 |
| Ascites | |||
| No | 1 | ||
| Yes | 1.41 | 1.11-1.81 | 0.005 |
| BCLC stage | |||
| A | 1 | ||
| B | 0.88 | 0.59-1.31 | 0.517 |
| C | 0.80 | 0.48-1.33 | 0.392 |
| D | 1.11 | 0.32-4.03 | 0.836 |
| Largest tumor | |||
| <5 cm | 1 | ||
| >5 cm | 1.12 | 0.90-1.40 | 0.317 |
| Tumor extent | |||
| Unifocal | 1 | ||
| Multifocal | 1.23 | 0.95-1.60 | 0.123 |
| | |||
| ECOG PS | |||
| 0 | 1 | ||
| >1 | 1.16 | 0.80-1.67 | 0.442 |
| Macrovascular invasion | |||
| No | 1 | ||
| Yes | 1.44 | 1.06-1.95 | 0.019 |
| Extrahepatic spread | |||
| No | 1 | ||
| Yes | 1.81 | 1.15-2.85 | 0.010 |
| First-line treatment | |||
| PEI/RFA/MWA | 1 | ||
| TACE | 1.28 | 0.91-1.79 | 0.156 |
| Sorafenib | 1.37 | 0.33-5.80 | 0.666 |
| BSC | 4.74 | 3.30-6.80 | <0.001 |
| Other | 1.18 | 0.75-1.85 | 0.473 |
| Low platelets + high MPV | |||
| No | 1 | ||
| Yes | 0.76 | 0.60-0.95 | 0.015 |
BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; MWA, microwave ablation; TACE, trans-arterial chemoembolization; BSC, best supportive care; MPV, mean platelet volume.